Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.
antigen presentation
gastrointestinal neoplasms
immunotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
02
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
5
2022
Statut:
ppublish
Résumé
Cross-presentation of exogenous antigens in HLA-class I molecules by professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent murine studies show that several non-professional APCs, including cancer-associated fibroblasts (CAFs) also possess this capacity. Whether human CAFs are able to cross-present exogenous antigen, which molecular pathways are involved in this process and how this ultimately affects tumor-specific CD8+ T cell function is unknown. In this study, we investigated the ability of human colorectal cancer (CRC)-derived CAFs to cross-present neoantigen-derived synthetic long peptides (SLPs), corresponding to tumor-derived mutant peptides, and how this affects tumor-specific T-cell function. Processing of the SLP was studied by targeting components of the cross-presentation machinery through CRISPR/Cas9 and siRNA-mediated genetic ablation to identify the key molecules involved in fibroblast-mediated cross-presentation. Multispectral flow cytometry and killing assays were performed to study the effect of fibroblast cross-presentation on T cell function. Here, we show that human CRC-derived CAFs display an enhanced capacity to cross-present neoantigen-derived SLPs when compared with normal colonic fibroblasts. Cross-presentation of antigens by fibroblasts involved the lysosomal protease cathepsin S. Cathepsin S expression by CAFs was detected in situ in human CRC tissue, was upregulated in ex vivo cultured CRC-derived CAFs and showed increased expression in normal fibroblasts after exposure to CRC-conditioned medium. Cognate interaction between CD8+ T cells and cross-presenting CAFs suppressed T cell function, reflected by decreased cytotoxicity, reduced activation (CD137) and increased exhaustion (TIM3, LAG3 and CD39) marker expression. These data indicate that CAFs may directly suppress tumor-specific T cell function in an antigen-dependent fashion in human CRC.
Sections du résumé
BACKGROUND
Cross-presentation of exogenous antigens in HLA-class I molecules by professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent murine studies show that several non-professional APCs, including cancer-associated fibroblasts (CAFs) also possess this capacity. Whether human CAFs are able to cross-present exogenous antigen, which molecular pathways are involved in this process and how this ultimately affects tumor-specific CD8+ T cell function is unknown.
METHODS
In this study, we investigated the ability of human colorectal cancer (CRC)-derived CAFs to cross-present neoantigen-derived synthetic long peptides (SLPs), corresponding to tumor-derived mutant peptides, and how this affects tumor-specific T-cell function. Processing of the SLP was studied by targeting components of the cross-presentation machinery through CRISPR/Cas9 and siRNA-mediated genetic ablation to identify the key molecules involved in fibroblast-mediated cross-presentation. Multispectral flow cytometry and killing assays were performed to study the effect of fibroblast cross-presentation on T cell function.
RESULTS
Here, we show that human CRC-derived CAFs display an enhanced capacity to cross-present neoantigen-derived SLPs when compared with normal colonic fibroblasts. Cross-presentation of antigens by fibroblasts involved the lysosomal protease cathepsin S. Cathepsin S expression by CAFs was detected in situ in human CRC tissue, was upregulated in ex vivo cultured CRC-derived CAFs and showed increased expression in normal fibroblasts after exposure to CRC-conditioned medium. Cognate interaction between CD8+ T cells and cross-presenting CAFs suppressed T cell function, reflected by decreased cytotoxicity, reduced activation (CD137) and increased exhaustion (TIM3, LAG3 and CD39) marker expression.
CONCLUSION
These data indicate that CAFs may directly suppress tumor-specific T cell function in an antigen-dependent fashion in human CRC.
Identifiants
pubmed: 35264435
pii: jitc-2021-003591
doi: 10.1136/jitc-2021-003591
pmc: PMC8915372
pii:
doi:
Substances chimiques
Cathepsins
EC 3.4.-
Peptide Hydrolases
EC 3.4.-
cathepsin S
EC 3.4.22.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
EMBO Rep. 2011 Dec 01;12(12):1257-64
pubmed: 22037009
Nat Rev Immunol. 2012 Jul 13;12(8):557-69
pubmed: 22790179
J Exp Med. 2018 Sep 3;215(9):2325-2337
pubmed: 30115740
J Immunol. 2005 Feb 1;174(3):1205-12
pubmed: 15661874
J Clin Invest. 1998 Jun 1;101(11):2351-63
pubmed: 9616206
Sci Immunol. 2018 Dec 7;3(30):
pubmed: 30530727
Int J Mol Sci. 2021 Dec 23;23(1):
pubmed: 35008560
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Nat Rev Immunol. 2016 Mar;16(3):193-201
pubmed: 26852928
Clin Cancer Res. 2013 Nov 1;19(21):5914-26
pubmed: 24052018
Respir Res. 2020 May 12;21(1):111
pubmed: 32398133
Cancer Immunol Immunother. 2011 Jul;60(7):953-63
pubmed: 21431917
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
J Biol Chem. 1992 Apr 15;267(11):7258-62
pubmed: 1373132
Immunity. 2004 Aug;21(2):155-65
pubmed: 15308097
J Immunol. 2002 May 1;168(9):4488-94
pubmed: 11970993
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
J Immunol. 2019 Jan 15;202(2):451-459
pubmed: 30559321
Oncogenesis. 2016 Feb 22;5:e198
pubmed: 26900950
J Biol Chem. 2011 Nov 4;286(44):38054-38059
pubmed: 21914809
Blood. 2017 Mar 9;129(10):1284-1295
pubmed: 28053195
Nat Biotechnol. 2000 Apr;18(4):405-9
pubmed: 10748520
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32098829
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
Nat Commun. 2018 Mar 5;9(1):948
pubmed: 29507342
J Clin Med. 2019 Nov 15;8(11):
pubmed: 31731701
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
J Proteomics. 2014 Sep 23;109:240-4
pubmed: 25050860
J Clin Invest. 2012 Mar;122(3):899-910
pubmed: 22293174
Trends Immunol. 2017 Jun;38(6):432-443
pubmed: 28499492
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Gastroenterology. 2008 Oct;135(4):1228-1237, 1237.e1-2
pubmed: 18760278
Oncogene. 2014 Jan 2;33(1):97-107
pubmed: 23208491
Mol Immunol. 2019 Sep;113:43-49
pubmed: 29627136
Gastroenterology. 2011 Jun;140(7):2019-30
pubmed: 21376048
Cell Rep. 2021 Apr 20;35(3):109009
pubmed: 33882319
Immunol Cell Biol. 2018 Feb;96(2):137-148
pubmed: 29363167
J Immunol. 2004 Sep 15;173(6):3844-54
pubmed: 15356132
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Ann Oncol. 2017 Dec 1;28(suppl_12):xii74
pubmed: 29253116
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
Nature. 2016 Aug 4;536(7614):91-5
pubmed: 27350335
Proteomics. 2018 Jun;18(12):e1700250
pubmed: 29251415
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Mol Cancer. 2021 Apr 29;20(1):73
pubmed: 33926453
Molecules. 2020 Nov 19;25(22):
pubmed: 33228004
Nat Commun. 2018 Nov 8;9(1):4692
pubmed: 30410077
Mol Immunol. 2015 Dec;68(2 Pt A):72-6
pubmed: 26006050
J Exp Med. 1998 Jan 5;187(1):97-104
pubmed: 9419215
Nat Rev Immunol. 2008 Aug;8(8):607-18
pubmed: 18641646
Mutat Res. 1999 May 14;434(1):17-27
pubmed: 10377945
Mol Cell Proteomics. 2013 Jul;12(7):1829-43
pubmed: 23481700
Int J Cancer. 1997 Jan 27;70(3):302-9
pubmed: 9033632
Mol Immunol. 1995 Dec;32(17-18):1377-85
pubmed: 8643107
Annu Rev Immunol. 2017 Apr 26;35:149-176
pubmed: 28125356